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Older women with type 2 diabetes mellitus (DM) have higher bone mineral density (BMD)
but also have higher rates of fracture compared to those without DM. Limited evidence
suggests that DM may also be associated with more rapid bone loss.To determine if bone
loss rates differ by DM status in older women, we analyzed BMD data in the Study of Osteo-
porotic Fractures (SOF) between 1986 and 1998. SOF participants were women ≥65 years
at baseline who were recruited from four regions in the U.S. DM was ascertained by self-
report. BMD was measured with dual-energy x-ray absorptiometry (DXA) at baseline and
at least one follow-up visit at the hip (N =6624) and calcaneus (N =6700) and, on a subset
of women, at the spine (N =396) and distal radius (N =306). Annualized percent change
in BMD was compared by DM status, using random effects models. Of 6,867 women
with at least one follow-up DXA scan, 409 had DM at baseline. Mean age was 70.8 (SD
4.7) years. Baseline BMD was higher in women with DM at all measured sites. In models
adjusted for age and clinic, women with prevalent DM lost bone more rapidly than those
without DM at the femoral neck (−0.96 vs. −0.59%/year, p<0.001), total hip (−0.98 vs.
−0.70%/year, p<0.001), calcaneus (−1.64 vs. −1.40%/year, p=0.005), and spine (−0.33
vs.+0.33%/year, p=0.033), but not at the distal radius (−0.97 vs.−0.90%/year, p=0.91).
These findings suggest that despite higher baseline BMD, older women with DM experi-
ence more rapid bone loss than those without DM at the hip, spine, and calcaneus, but
not the radius. Higher rates of bone loss may partially explain higher fracture rates in older
women with DM.
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INTRODUCTION
Type 2 diabetes mellitus (DM) and osteoporosis are two chronic
conditions whose prevalence and associated costs continue to
increase, particularly among the elderly. Internationally, over 10%
of adults age 60 years and older have DM; in the U.S. the prevalence
of DM in this age group is nearly 30% (Wild et al., 2004; Cowie
et al., 2009). The annual number of hip fractures worldwide was
estimated as 1.26 million in 1990, and is projected to approxi-
mately double by 2025 (Gullberg et al., 1997). In older adults,
considerable overlap in DM and osteoporosis would be expected
simply due to the high prevalence of each condition. In addi-
tion, DM is associated with increased risk of fracture (Janghorbani
et al., 2007; Vestergaard, 2007). Paradoxically, cross-sectional stud-
ies have demonstrated that DM is associated with normal or higher
bone mineral density (BMD) (Buysschaert et al., 1992; Bauer et al.,
1993; Orwoll et al., 1996; Vestergaard, 2007). Thus, for any given
BMDT -score, the fracture risk in those with DM tends to be higher
than the corresponding risk for non-diabetic patients (Schwartz
et al., 2011).
Although DM is associated with higher baseline BMD, there is
some evidence that people with DM may have more rapid bone
loss. This could partially account for higher fracture risk at a given
BMD since rapid bone loss contributes to fracture risk indepen-
dent of baseline BMD (Hillier et al., 2007; Ahmed et al., 2010;
Cawthon et al., 2012). However, previous reports on the rate of
bone loss in older adults with DM have been inconsistent. While
several studies have reported accelerated bone loss at the hip in
older women with DM, including in the Study of Osteoporotic
Fractures (SOF) (Keegan et al., 2004; Cauley et al., 2009; Khalil
et al., 2011), slower bone loss has also been reported at the spine
(Khalil et al., 2011) and radius (Krakauer et al., 1995). Our goals
in this study were to clarify the effects of diabetes on the rate
of bone loss and to gain insight into the seemingly paradoxi-
cal and poorly understood relationships among diabetes, BMD,
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and fracture. To achieve these goals, we studied the associations
between diabetes and rate of bone loss at several skeletal sites
in older women enrolled in the Study of Osteoporotic Fractures
(SOF), using longitudinal data from 1986 to 1998.
MATERIALS AND METHODS
PARTICIPANTS
The Study of Osteoporotic Fractures (SOF) is a prospective cohort
of 9,704 white women aged≥65 years. Participants were recruited
from the community in four U.S. regions: Portland, Oregon;
Minneapolis, Minnesota; Baltimore County, Maryland; and the
Mononghela Valley near Pittsburgh, Pennsylvania. Enrollment
began in 1986, and the current analyses are based on follow-
up data through 1998 (Cummings et al., 1990). Women were
recruited irrespective of BMD and fracture history; those unable to
walk without assistance and those with bilateral hip replacements
were excluded. All women provided written consent, and SOF was
approved by the Institutional Review Board at each site.
ASCERTAINMENT OF DIABETES MELLITUS
At baseline, participants were asked if a physician had ever told
them that they had diabetes or “sugar diabetes.” Women who
answered “yes” to this question were identified as having preva-
lent DM. Twenty-five women did not answer this question and
were excluded. Using the same survey question, incident DM was
defined at years 3.5, 6, 8, and 10 (corresponding to SOF clinic visits
3, 4, 5, and 6) and via medication inventory at years 6, 8, and 10.
Women who did not report diabetes but who were taking diabetic
medications were classified as having DM. Nine women included
in these analyses reported thiazolidinedione (TZD) use at year 10.
MEASUREMENT OF BONE MINERAL DENSITY
Calcaneal BMD
Peripheral BMD was measured at the calcaneus using single
photon absorptiometry (Osteoanalyzer; Dove Medical Systems)
(Cummings et al., 1990) at the baseline, year 6 and year 8 visits
in all women and at the year 10 visit in a subset of participants
(Figure 1). Of the 9,679 women with baseline DM data, 6,700
women had ≥2 calcaneal measurements and were included in
analyses examining the association between DM and change in
calcaneal BMD.
Radial BMD
Distal and proximal radial BMD were measured by single photon
absorptiometry. The distal measurement site was just proximal to
the junction of the ulna and radius, and the proximal site was 25%
of the total ulnar length distant from the distal site (Cummings
et al., 1990). Radial scans were obtained in all women at baseline
and in a small subset of women at year 6. Of the 9,679 women with
baseline DM data, 306 had distal BMD measurements and 290 had
proximal BMD measurements at both visits and were included in
analyses examining the association between DM and changes in
distal and proximal radial BMD (Figure 1).
Hip and spine BMD
Bone mineral density of the total hip, femoral neck, and total lum-
bar spine was first measured at year 2 (visit 2) using dual-energy
FIGURE 1 | Number of participants in each bone loss analysis by
diabetes status at each visit. N, number of participants included in
analysis of each skeletal site; non-DM, no DM at current or previous visits;
PrevDM, DM at baseline; IncDM, new diagnosis of DM between baseline
and current visit.
x-ray absorptiometry (DXA) with Hologic QDR-1000 scanners
(Hologic, Inc., Bedford, MA, USA). Hip BMD was measured again
at years 6 and 8 on the same scanners. At year 10, hip BMD was
measured with QDR-1000 scanners for 4,224 women and with
QDR-2000 scanners for 346 women. Of the 9,679 women with
baseline DM data, 6,624 had ≥2 hip BMD measurements and
were included in analyses examining the association between DM
and BMD at the total hip and femoral neck (Figure 1). A subset of
the 9,679 women had spine BMD measured at year 6 (N = 479),
with 396 having spine BMD measurements at both years 2 and 6;
these women were included in analyses examining the association
between DM and spine BMD.
OTHER MEASUREMENTS
Weight was measured on a standard balance beam scale,and weight
change was calculated by subtracting baseline weight (or year 2
weight for the spine and hip analyses) from current weight. Height
was measured by a Harpenden stadiometer (Holtain Ltd., Dyved,
UK). Self-reported height at age 25 was collected at baseline; height
change was calculated by subtracting height at age 25 from base-
line height. Self-reported age at the last menstrual period (LMP)
was collected at baseline, and number of years since menopause
was calculated by subtracting age at LMP from baseline age (or
from year 2 age for hip and spine BMD models). Current use
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of vitamin D and calcium supplements, estrogen preparations,
thiazide diuretics, and oral steroids was self-reported at baseline
and year 2. Beginning in year 6, participants were asked to bring
all prescription and non-prescription medications to the clinic
visit for a medication inventory. Self-reported use of calcitonin
injections and fluoride pills started at year 2, and self-reported
use of etidronate started at year 6. Tobacco use and walking for
exercise were self-reported at each visit. Various aspects of physi-
cal performance were assessed by trained examiners at each visit.
These included grip strength (measured with a handheld Jamar
dynamometer using the average of two trials per hand) (Cum-
mings et al., 1995; Seeley et al., 1995), gait speed (measured on a
6-m walking course using the time to complete two trials (Cum-
mings et al., 1995), and ability to rise from a chair five times
without using arms (Cummings et al., 1995; Seeley et al., 1995).
Peripheral nerve function was assessed at year 2 using esthesiome-
ter testing on the warmed great toe of both feet, using six filaments
of increasing size (3.22–6.10, logarithm of force applied, in 0.1 g).
Women who felt only the 6.10 filament or no filament on either
toe were identified as having poor light touch discrimination.
STATISTICAL ANALYSES
Characteristics of participants were examined according to base-
line DM status, using t -tests for continuous variables and chi-
square tests for categorical variables. Since spine and radial BMD
were measured at only two time points, linear regression was used
to examine the association between DM and change in BMD at
these sites, with results presented as least square means. By con-
trast, since hip and calcaneal BMD were measured at several time
points, random effects models were used to examine the asso-
ciation between DM and change in BMD at these sites. These
models account for the between-subject variation and within-
subject correlations among repeated BMD measurements. Time
was modeled as a continuous covariate, measured as the number
of years between the first BMD and the follow-up BMD scans
for each site. Random effects models included the intercept and
slope of the BMD measurements over time, thereby allowing for
individual time trends for each participant.
All models were adjusted for age and clinic site. The following
covariates were initially considered for inclusion in the multivari-
ate models: baseline (or year 2) weight, weight change, baseline (or
year 2) height, height loss since age 25, and current use of any of the
following: vitamin D, calcium supplements, estrogen, osteoporosis
medications (alendronate, raloxifene, tamoxifen, etidronate, flu-
oride pills, or calcitonin injections), thiazide, and oral steroids.
Also considered for inclusion in the models were current grip
strength, walking speed, ability to rise from chair, walking for exer-
cise, years since menopause, current tobacco use, and poor light
touch discrimination at year 2. These covariates were included in
the multivariate model if they were significantly associated both
with DM in univariate analyses and with change in BMD in the
age-clinic-adjusted models at p-value< 0.10. Separate multivari-
ate models were constructed for each skeletal site. Weight loss was
added separately to the multivariate models to assess its role as a
potential intermediary between DM and change in BMD because
it is known to predict bone loss from other studies (Ensrud et al.,
2003), and DM is associated with weight loss in the SOF cohort.
Change in BMD is reported as annualized percent change. For
hip and calcaneal BMD, the mixed model estimates were used to
estimate BMD at each year of follow-up and plotted to visualize
changes in BMD over time for each of the DM groups. All analyses
were conducted using SAS version 9.1 (SAS Institute Inc., Cary,
NC, USA).
RESULTS
Of the 9,679 women at baseline with known diabetes status, 6,867
had≥2 BMD measurements during the first 10 years of follow-up.
Of these, 409 (6%) self-reported a physician diagnosis of diabetes
at baseline and were categorized as having prevalent DM. Of the
remaining 6,458 women who were not diabetic at baseline, 399
(6%) developed incident DM during follow-up. Characteristics of
the 6,867 women included in one or more of these analyses are
presented in Table 1. Compared to non-diabetic women, women
with prevalent DM had higher baseline BMD at all six sites. Women
with prevalent DM had lower grip strength, slower walking speed,
and were less likely to walk for exercise and to report estrogen use.
Use of alendronate or raloxifene was similar in women with and
without DM.
DIABETES AND CHANGE IN HIP BMD
Among the 6,624 women with ≥2 hip BMD measurements
between years 2 and 10, 391 and 303 had prevalent and incident
DM, respectively. In age and clinic-adjusted models for the femoral
neck, women with prevalent DM, incident DM, and those with-
out DM lost an average of 0.96%, 0.90, and 0.59 BMD %/year,
respectively (Table 2). At the total hip, both prevalent and inci-
dent DM lost 0.98%/year, while non-DM women lost an average
of 0.70%/year. Although bone loss was more rapid in women
with prevalent DM, average BMD remained higher compared with
non-DM women throughout 8 years of follow-up (Figure 2).
In multivariate models, mean BMD loss remained significantly
greater for the women with prevalent DM compared to women
without DM at both the femoral neck (−0.86 vs. −0.54%/year,
p< 0.001) and total hip (−0.86 vs.−0.59%/year,p< 0.001). Addi-
tional adjustment for concurrent weight change slightly attenu-
ated, but did not eliminate, the association between prevalent DM
and accelerated BMD loss (Table 2). For incident DM compared to
women without DM, multivariate adjustment attenuated the asso-
ciations for femoral neck (−0.79 vs. −0.54%/year, p= 0.06) and
total hip (−0.77 vs. −0.59%, p= 0.06) BMD, and they were no
longer statistically significant (Table 2). Further adjustment for
concurrent weight change resulted in additional attenuation of
these relationships comparing women with incident DM to those
without DM.
DIABETES AND CHANGE IN CALCANEAL BMD
Of the 6,700 women with ≥2 calcaneal BMD measurements
between baseline and year 10, 387 and 306 had prevalent and
incident DM, respectively. Adjusted for age and clinic, women
with prevalent DM lost an average of 1.6%/year, while those with
incident DM and non-DM women lost 1.4%/year (Table 2). Cal-
caneal BMD was highest among women with prevalent DM, but
declined more rapidly over time. Although bone loss was more
rapid in those with prevalent DM, average BMD remained higher
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Table 1 | Characteristicsa of women by diabetes status.
Non-DM Prevalent DM p-Value
(N =6458) (N =409)
Age (years) 70.7±4.7 71.0±4.6 0.35
Weight (kg) 67.1±12.0 72.6±14.8 <0.001
Change in weight (V6-BL)
(%/year)
−0.25±0.96 −0.41±0.99 0.012
Height (cm) 159.6±5.9 158.9±6.1 0.017
Height loss since age 25 (cm) 3.1±2.8 2.9±2.6 0.095
Years since menopause
(years)
23.6±7.8 24.7±8.1 0.006
Current smoker 573 (8.9) 34 (8.3) 0.69
Current vitamin D use 2958 (46.6) 149 (36.9) <0.001
Current calcium use 2871 (44.6) 134 (32.8) <0.001
Current estrogen use 1226 (19.5) 42 (10.4) <0.001
Alendronate taken in last
2 years (V6)
479 (8.9) 18 (6.6) 0.18
Current raloxifene use (V6) 8 (0.2) 1 (0.4) 0.36
Current thiazide use 1513 (23.7) 153 (37.8) <0.001
Current statin use (V4) 248 (3.9) 22 (5.5) 0.12
Current oral steroid use 110 (1.7) 4 (1.0) 0.27
Grip strength (kg) 21.3±4.1 20.8±4.4 0.020
Walking speed (m/s) 1.05±0.20 0.96±0.21 <0.001
Inability to rise from chair 142 (2.2) 14 (3.4) 0.10
Walk for exercise 3478 (53.9) 189 (46.2) 0.003
Poor light touch discrimination
(V2)
240 (4.3) 35 (9.9) <0.001
Baseline BMD
Calcaneus BMD (g/cm2) 0.41±0.09 0.44±0.10 <0.001
Distal radius BMD (g/cm2) 0.36±0.08 0.39±0.08 <0.001
Proximal radius BMD (g/cm2) 0.64±0.1 0.67±0.1 <0.001
Femoral neck BMD (V2)
(g/cm2)
0.65±0.11 0.69±0.12 <0.001
Total hip BMD (V2) (g/cm2) 0.76±0.13 0.81±0.14 <0.001
Total lumbar spine BMD (V2)
(g/cm2)
0.86±0.17 0.9±0.17 <0.001
Mean (SD), or N (%). BMD, bone mineral density; DM, diabetes mellitus.
aMeasurement at baseline visit unless otherwise indicated.
compared with non-DM women even after 10 years of follow-
up (Figure 3). The difference in mean loss between the preva-
lent DM and non-DM groups was significant in the age- and
clinic-adjusted model, of borderline significance in the multivari-
ate model, and not significant in a model adjusting for weight
change. There was no difference in BMD loss between women
with incident DM and those without DM in any of the calcaneal
models.
DIABETES AND CHANGE IN LUMBAR SPINE BMD
Of the 396 women with lumbar spine BMD measurements at
years 2 and 6, 20 had prevalent DM and 9 developed incident
DM. Adjusted for age and clinic, women with prevalent DM
lost BMD (−0.33%/year), while those without DM gained bone
(0.33%/year; p= 0.03) (Table 3). Numbers were too small to assess
incident DM separately. Results were similar with multivariable
adjustment, including adjustment for concurrent weight change.
DIABETES AND CHANGE IN RADIAL BMD
Of the 306 women with distal BMD measurements at baseline
and year 6, 15 had prevalent DM at baseline and 9 women devel-
oped incident DM between baseline and year 6. After adjustment
for age and clinic site, women with prevalent DM lost an aver-
age of 0.97%/year at the distal radius while non-DM women lost
0.90%/year (p= 0.91) (Table 3). Numbers were too small to assess
incident DM separately. Multivariable adjustment did not substan-
tially alter these results. Of the 290 women with two proximal BMD
measurements, 15 had prevalent DM and 7 developed incident
DM. Adjusted for age and clinic site, women with prevalent DM
gained an average of 0.74%/year at the proximal radius while non-
DM women lost 0.33%/year (p= 0.14). Multivariate adjustment
did not substantially alter these results.
DISCUSSION
Despite their higher baseline BMD, older women with prevalent
DM had more rapid bone loss at the total hip, femoral neck, lum-
bar spine, and calcaneus, but not at the distal or proximal radius,
than their non-diabetic counterparts. These results strengthen the
evidence for an association between DM and accelerated bone loss,
but also clarify that this relationship is site-specific. Our findings
extend a previous report from the SOF cohort that DM is associ-
ated with accelerated bone loss at the total hip (Cauley et al., 2009),
and are in agreement with previous observations of more rapid
bone loss at the hip among postmenopausal women with DM in
the Health, Aging, and Body Composition Study (Health ABC)
and in the placebo group of the Fracture Intervention Trial (FIT)
(Keegan et al., 2004; Schwartz et al., 2005). In FIT, there was also a
trend toward a faster rate of bone loss at the spine among diabetic
women but the difference was not statistically significant (Keegan
et al., 2004). Similarly, the Study of Women’s Health Across the
Nation (SWAN) found an increased rate of bone loss at the total
hip among women with DM in the post menopausal but not per-
imenopausal time period (Khalil et al., 2011). However, SWAN, in
contrast to our findings, reported a slower rate of bone loss at the
spine in women with DM. Another study found a slower rate of
bone loss at the radius over 12 years in 19 adults with DM (average
age 52 years), based on BMD z-scores (Krakauer et al., 1995). By
comparison, we found no differences in the rate of bone loss at the
radius.
Thiazolidinedione use may contribute to more rapid bone loss
in those with DM. In randomized controlled trials,TZDs have been
shown to increase bone loss at the spine and total hip (Berberoglu
et al., 2007; Grey, 2008; Borges et al., 2011). However, our findings
are not explained by TZD use. The vast majority of follow-up of
the SOF cohort took place before the introduction of troglitazone
in 1997 and of rosiglitazone and pioglitazone in 1999. Indeed, only
nine participants in these analyses reported TZD use at year 10.
Our findings indicate that more rapid bone loss associated with
DM is a feature of the hip, spine, and calcaneal sites, but not the
radius. In comparison with the other three sites, the radius has a
higher proportion of cortical bone and is a non-weight bearing
site. In theory, the lack of effect of DM at the radius could result
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Table 2 | Adjusted mean BMD change at the hip and calcaneus by diabetes status.
Site of BMD Change Prevalent DM Incident DM Non-DM
Change
(%/year)
95% CI p* Change
(%/year)
95% CI p** Change
(%/year)
95% CI
FEMORAL NECK
Adjusted for age and site −0.96 −1.17, −0.77 <0.001 −0.90 −1.22, −0.59 0.009 −0.59 −0.66, −0.53
MV without weight changea −0.86 −1.10, −0.63 <0.001 −0.79 −1.14, −0.44 0.06 −0.54 −0.62, −0.46
MV with weight changea −0.79 −1.03, −0.57 <0.001 −0.69 −1.04, −0.36 0.18 −0.51 −0.59, −0.44
TOTAL HIP
Adjusted for age and site −0.98 −1.15, −0.82 <0.001 −0.98 −1.22, −0.75 0.001 −0.70 −0.76, −0.65
MV without weight changea −0.86 −1.06, −0.68 <0.001 −0.77 −1.03, −0.52 0.06 −0.59 −0.66, −0.53
MV with weight change −0.75 −0.92, −0.58 <0.001 −0.61 −0.86, −0.38 0.51 −0.55 −0.61, −0.50
CALCANEUS
Adjusted for age and site −1.64 −2.06, −1.25 0.005 −1.43 −2.64, −0.40 0.94 −1.40 −1.54, −1.27
MV without weight changeb −1.29 −1.75, −0.86 0.06 −0.83 −2.13, 0.27 0.57 −1.08 −1.24, −0.93
MV with weight change −1.19 −1.65, −0.76 0.14 −0.68 −1.96, 0.40 0.44 −1.04 −1.19, −0.88
*p-Value for differential rate of BMD loss for prevalent DM vs. non-DM.
**p-Value for differential rate of BMD loss for incident DM vs. non-DM.
aAdjusted for baseline age, clinic site, baseline height, baseline weight, height change since 25 years since menopause, current vitamin D use, current calcium use,
current estrogen use, current use of osteoporosis medications, current thiazide diuretic use, current grip strength, current walking speed, current inability to rise from
chair without use of arms, and decreased light touch.
bAdjusted for baseline age, clinic site, baseline weight, baseline height, height change since age 25, years since menopause, current vitamin D use, current estrogen
use, current thiazide use, current grip strength, current walking speed, current inability to rise from chair without use of arms, and current walking for exercise.
FIGURE 2 | BMD over time at the femoral neck among older women by diabetes status. Mixed model estimates, adjusted for age and clinic site, were
used to estimate BMD at each year of follow-up.
from a stronger association with loss of trabecular rather than cor-
tical bone, but cross-sectional studies suggest the opposite (Melton
et al., 2008; Petit et al., 2010; Shu et al., 2012; Patsch et al., 2013). To
our knowledge, longitudinal studies using quantitative computed
tomography (QCT) are not currently available to help disentangle
the effect of DM on cortical compared with trabecular bone loss.
Another possible explanation is a stronger effect of DM on bone
loss in the presence of loading. Other studies indicate that bone
geometry, although not bone density, may be negatively affected
by DM with a reduction in bone strength relative to load (Petit
et al., 2010; Ishii et al., 2012). DM is associated with higher lev-
els of sclerostin (Garcia-Martin et al., 2012), indicating an effect
on osteocytes, and with reduced bone formation (Krakauer et al.,
1995; Shu et al., 2012). DM may inhibit the ability of osteocytes
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FIGURE 3 | BMD over time at the calcaneus among older women by diabetes status. Mixed model estimates, adjusted for age and clinic site, were used
to estimate BMD at each year of follow-up.
Table 3 | Adjusted mean BMD change at the spine and radius by diabetes status.
Site of BMD Change Prevalent DM Non-DM
Change
(%/year)
95% CI p-value* Change
(%/year)
95% CI
SPINE
Adjusted for age and site −0.33 −0.92, 0.26 0.03 0.33 0.20, 0.47
MV without weight changea −0.41 −0.98, 0.17 0.01 0.35 0.21, 0.48
MV with weight change −0.36 −0.92, 0.21 0.02 0.34 0.21, 0.47
DISTAL RADIUS
Adjusted for age and site −0.97 −2.01, 0.08 0.91 −0.90 −1.14, −0.66
MV without weight changeb −1.12 −2.18, −0.07 0.68 −0.89 −1.14, −0.65
MV with weight change −1.13 −2.18, −0.08 0.67 −0.89 −1.13, −0.65
PROXIMAL RADIUS
Adjusted for age and site 0.74 −0.63, 2.11 0.14 −0.33 −0.65, −0.01
MV without weight changeb 0.71 −0.67, 2.09 0.15 −0.35 −0.67, −0.02
MV with weight change 0.71 −0.68, 2.09 0.15 −0.35 −0.67, −0.02
*p-Value compared to non-DM.
aAdjusted for age, clinic site, weight, thiazide diuretic use, and vitamin D use.
bAdjusted for age, clinic site, weight, walking for exercise, height change since age 25, and vitamin D use.
and osteoblasts to respond adequately to load. Thus, at skeletal sites
that experience loading, older women with DM may experience
greater net loss of bone.
Our results showing higher BMD at baseline are consistent
with meta-analyses reporting higher BMD associated with DM
(Vestergaard, 2007; Ma et al., 2012). Yet, surprisingly, DM was also
associated with more rapid bone loss at the hip, spine, and cal-
caneus. The rate of bone loss was accelerated among those with
incident DM at the hip, but not the calcaneus. Thus, at least for
the hip, our results suggest that even at diagnosis, DM has an
unfavorable impact on BMD. We also found more rapid weight
loss among the diabetic women, despite higher baseline weight.
Previous studies have also reported more rapid weight loss with
DM (Moritz et al., 1994; Looker et al., 2001; Schwartz et al., 2005).
While weight loss is a hallmark of poorly controlled DM, more
rapid weight loss was also observed in those with relatively good
control (Looker et al., 2001). Weight loss is a strong risk factor for
bone loss (Hannan et al., 2000), and more rapid bone loss among
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diabetic women appears to account in part for more rapid bone
loss in our study. However, if weight loss were the only mechanism,
we would expect our models that included concurrent weight loss
to abolish the relationship between bone loss and DM. Instead,
although adjustment for concurrent weight change attenuated the
effect of accelerated BMD loss among women with prevalent DM,
it did not abolish the effect. This indicates that more rapid weight
loss does not account for the more rapid bone loss that we observed
in women with DM.
Other possible mechanisms for accelerated bone loss with DM
include lower levels of insulin-like growth factor 1, changes in cal-
cium homeostasis, increased advanced glycation end products, and
decreased blood flow to the lower extremities (Raskin et al., 1978;
Vogt et al., 1997; Schwartz et al., 2009). Higher levels of inflamma-
tory cytokines or oxidative stress in those with DM may also drive
bone loss (Clowes et al., 2005; Cauley et al., 2007; Manolagas and
Almeida, 2007). Reduced exercise in those with DM may increase
bone loss (Greendale et al., 1995), but adjustment for physical
activity in our models did not account for the observed associ-
ation between DM and rate of bone loss. Thus, the mechanisms
underlying the association between DM and accelerated bone loss
merit further exploration.
It has been shown that BMD T -score and FRAX underestimate
fracture risk in DM women (Schwartz et al., 2011; Giangregorio
et al., 2012). Accelerated bone loss with DM may be a contribut-
ing factor as the rate of bone loss predicts fractures independent
of baseline BMD (Nguyen et al., 2005; Sornay-Rendu et al., 2005;
Bruyere et al., 2007; Hillier et al., 2007; Berger et al., 2009; Ahmed
et al., 2010; Cawthon et al., 2012). The reasons for the association
between more rapid bone loss and fracture remain controversial.
More rapid bone loss may simply be a marker for a lower BMD
closer to the time of the fracture. In support of this hypothesis, in
the Tromso study the rate of bone loss was no longer associated
with fracture risk when models were adjusted for the final BMD
measurement, closer to the time of fracture (Ahmed et al., 2010).
In contrast, in the Study of Osteoporosis in Men (MrOS) cohort
the rate of bone loss predicted hip fracture independent of baseline
BMD and final BMD measurements (Cawthon et al., 2012), sug-
gesting that more rapid bone loss may be a marker for changes in
bone strength that cannot be fully captured by DXA. Fracture in
diabetic women is associated with increased cortical porosity, a fea-
ture of bone that is not appreciated with DXA scans (Patsch et al.,
2013). In our analyses, although DM women had more rapid bone
loss, they continued to have higher average hip BMD compared
with non-DM women, even after 8 years of follow-up.
Strengths of our study include up to 10 years of follow-up for
BMD changes and the ability to adjust for multiple potential con-
founders, including use of estrogen and osteoporosis medications.
A limitation of our study is the relatively small number of women
with BMD scans of the spine and radius. Another limitation of
this study is the lack of blood tests for ascertainment of DM. It is
likely that some participants had undiagnosed diabetes and were
incorrectly classified as not having diabetes (Schneider et al., 2012).
This misclassification should not have differed by levels of the out-
come, changes in BMD. Thus, any misclassification would tend to
bias our measures of association between diabetes and change in
BMD toward the null. In addition, SOF participants were com-
munity dwelling white women, and these results may not apply
to other populations. Although analyses were adjusted for multi-
ple factors, the possibility of residual confounding due to factors
that were not measured or were measured with error cannot be
eliminated.
In conclusion, older women with DM had accelerated bone
loss at the hip, spine, and calcaneus, but not at the radius, com-
pared to women without diabetes. Greater concurrent weight
loss in the women with DM accounted for some, but not all, of
the association between DM and accelerated BMD loss, suggest-
ing that other diabetes-related mechanisms increase bone loss.
Despite higher baseline BMD, accelerated bone loss may account,
at least in part, for the increased fracture rate observed with
DM.
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